Download Composite-presentation

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Cancer Among Native Americans in
Arizona and New Mexico
Data Provided by
Arizona Cancer Registry at the
Arizona Department of Health Services
and the
New Mexico Cancer Council
©2012 MFMER | slide-2
Cancer Rate by Race/Ethnicity, Arizona, 2005-2009
Age-adjusted incidene rate per 100,000
500
Male
Female
400
300
200
100
0
White, Non
Hispanic
White,
Hispanic
Black
American
Indian
Asian/Pacific
Islander
©2012 MFMER | slide-4
Age when Diagnosed with Cancer
(Arizona Native Americans, 2005-2009)
©2012 MFMER | slide-5
HIGH PREVENTION POTENTIAL
©2012 MFMER | slide-6
Yearly average count of new cancers among
Arizona Native Americans
Cancer Sites
Breast
Male
Female
1
58
Prostate
56
Colorectal
30
25
Kidney/Renal Pelvis
30
14
Corpus Uteri
27
Lung and Bronchus
11
11
Stomach
14
6
8
11
Other sites combined
48
33
Liver and Intrahepatic Bile Duct
12
6
Thyroid
4
12
Leukemia
9
7
Non-Hodgkin Lymphoma
Ovary
14
Gallbladder and Other Biliary
5
9
Pancreas
6
7
Oral Cavity
7
4
Cervix Uteri
11
Myeloma
5
5
Brain and Other Nervous System
6
4
Source: ACR, 2005-2009
©2012 MFMER | slide-11
©2012 MFMER | slide-12
CONCLUSIONS
• AIAN elders increasing proportion of the
population
• Cancer screening will be an important aspect of
maintaining health as people age
• Looking at the “whole person” remains the most
important determinant for good care
©2012 MFMER | slide-13
Introduction to Myeloma:
Diagnosis, Treatment, Risk Factors
and Prevalence
Scottsdale, Arizona
Rochester, Minnesota
Jacksonville, Florida
Alan Bryce, MD
Staff Oncologist, Mayo Clinic Arizona
Multiple Myeloma - Introduction
• Myeloma is a cancer of the Plasma Cells
• They grow out of control in the bone marrow (at least
10% and as high as nearly 100%)
• This results in many problems including:
• Low hemoglobin (anemia) and platelets
• Elevated abnormal immunoglobulins (proteins)
• Bone pain and fractures
• Infections (partly due to low normal
immunoglobulins)
• Kidney problems
• Other complications…
Spectrum of Myeloma
Normal
plasma
cell
MGUS
Monoclonal
gammopathy
of unknown
significance
Asymptomatic
Myeloma
Active
Myeloma
Aggressive
Myeloma
How do plasma cells become “evil”?
Multiple Myeloma – Causes?
• The cause of myeloma is still unknown
• Some have suggested:
• Radiation- Nuclear Bomb Survivors
• Chemicals (benzenes), herbicides and
insecticides- The “Myeloma Belt”
• Genetics or even viruses
• Familial Myeloma – still rare
• However, nothing is conclusive, and it is likely a
combination of many factors…
Multiple Myeloma
• Unfortunately, MM is not a curable disease (yet!!)
• Historically most people did not live for much more
than 2 years…
• However, the average survival is now at least 8 years
• This has been a result of three key
developments:
1. Early Detection
2. Autologous Stem Cell Transplant
3. Novel Drugs (thalidomide, bortezomib,
lenalidomide)
Age-adjusted incidence rate per
100,000 population
Myeloma rate in Arizona among race groups,
1995-2009
12
10
10.8
Male
8
Female
7.1
6
4
2
5.1
6.9
5.6
4.8
3.1
3.7
2.6
1.2
0
White, Non
Hispanic
White,
Hispanic
Black
American
Indian
Asian/Pacific
Islander
Race/Ethnic Group
©2012 MFMER | slide-20
Common Symptoms
•
•
•
•
•
•
•
Not all patients will have all of these symptoms
Fatigue
Lack of Appetite
Infection
Bone Pain
Kidney Failure
Confusion, dehydration, and constipation (high calcium)
Myeloma Treatment
• Principles of therapy
• 1. Stop the production of the abnormal plasma cells
(chemo)
• 2. Strengthen the bone and prevent fractures
• 3. Increase the hemoglobin count and reduce fatigue
• 4. Reduce risk of infections
• 5. Promote well being and quality of life
Conclusions
• New Treatments for myeloma have improved
survival
• Myeloma is usually preceded by many years of
MGUS
• Screening and early detection can allow therapy
to begin before organ damage develops
• Bone Marrow transplant and Clinical Trials
should be considered when appropriate
©2012 MFMER | slide-23
Related documents